✨ Free AI Report
Collegium Pharmaceutical, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Collegium Pharmaceutical, Inc.
Company Research

Collegium Pharmaceutical, Inc.: Business Overview, Financials & Competitive Analysis

Collegium Pharmaceutical, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Strong operational execution and portfolio diversification offset regulatory headwinds and generic competition risks in the specialty pharma space. With a market cap of $1.46B and trailing twelve-month revenue of $757M, Collegium demonstrates solid financial scale. The company delivered earnings and revenue surprises of +19.68% and +10.35% for Q3 2025.

What is Collegium Pharmaceutical, Inc.'s industry? Collegium Pharmaceutical, Inc. (collegiumpharma.com) operates in Specialty Pharmaceuticals - Pain Management & Neuropsychiatry. AskCyborg classifies Collegium Pharmaceutical, Inc. under Specialty Pharmaceuticals - Pain Management & Neuropsychiatry in its company registry.

Collegium Pharmaceutical is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company specializes in the development and c...

7/ 10Strong

Cyborg Score thesis

Strong operational execution and portfolio diversification offset regulatory headwinds and generic competition risks in the...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals - Pain Management & Neuropsychiatry
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Collegium Pharmaceutical, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Collegium Pharmaceutical, Inc.

AskCyborg analysts argue the bull and bear cases for Collegium Pharmaceutical, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Collegium Pharmaceutical, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Collegium Pharmaceutical, Inc. Overview

Pro stress-test →

Collegium Pharmaceutical is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company specializes in the development and commercialization of medicines for pain management. The September 2024 acquisition of Ironshore added Jornay PM and expanded Collegium into neuropsychiatry.

Strategic Profile

Pro stress-test →

Collegium is engaged in developing and commercializing abuse-deterrent products incorporating its patented DETERx platform technology, designed to maintain extended-release and safety profiles in the face of various abuse methods. Disciplined acquisitions and targeted investments in ADHD therapies diversify the portfolio and reduce risk, supporting stable long-term earnings.

Competitive Landscape

Pro stress-test →

SCILEX Holding, Lannett Company, Pfizer Manufacturing Austria, and Acura Pharmaceuticals are among Collegium's 32 competitors. As a specialty pharmaceutical company focused on pain management, Collegium competes in the prescription pain management and abuse-deterrent opioid segments. Over the past year, COLL exceeded both the US Pharmaceuticals industry return of 25.1% and the US Market return of 15.5%.

Industry Context

Collegium Pharmaceutical, Inc. operates in Specialty Pharmaceuticals - Pain Management & Neuropsychiatry.

Key facts

Founded: 2002 · Headquarters: Stoughton, MA · Revenue: $757M · Market cap: $1.46B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Collegium Pharmaceutical, Inc..

  • Collegium generated record quarterly net revenue of $188.0 million in Q2 2025, up 29% year-over-year, with Jornay PM net revenue of $32.6 million growing 23% YoY.
  • As of January 31, 2026, there were 31,753,211 common shares outstanding with aggregate market value of approximately $926.4 million.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Collegium reported strong Q3 2025 results, beating analyst expectations and raising full-year guidance.
  • July 2025Board authorized a new $150 million share repurchase program replacing the previous program that expired June 30, 2025.
  • +1 moreTrack every material event for Collegium Pharmaceutical, Inc. as it happens. Explore monitoring →
Get alerted when Collegium Pharmaceutical, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Pain Management PortfolioRegional anesthetic and pain management solutions→ADHD TreatmentsNeuropsychiatric and ADHD therapies→Opioid AlternativesGastrointestinal and opioid-related treatments→Abuse-Deterrent OpioidsAbuse-deterrent pain management formulations→

Compare Collegium Pharmaceutical, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Collegium Pharmaceutical, Inc. operates in Specialty Pharmaceuticals - Pain Management & Neuropsychiatry. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Pharmaceuticals - Pain Management & Neuropsychiatry research →
NEW · MCP server

Ask your AI assistant about Collegium Pharmaceutical, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Collegium Pharmaceutical, Inc. and its top competitor on Cyborg Score”
“What did Collegium Pharmaceutical, Inc. do this quarter?”
“Is Collegium Pharmaceutical, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Collegium Pharmaceutical, Inc. do?+
Collegium Pharmaceutical is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company specializes in the development and c...
What is Collegium Pharmaceutical, Inc.'s Cyborg Score?+
Collegium Pharmaceutical, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Collegium Pharmaceutical, Inc.'s main competitors?+
Named competitors include Pain Management Portfolio, ADHD Treatments, Opioid Alternatives, Abuse-Deterrent Opioids. The full competitive landscape is in the AskCyborg report.
How can I get the full Collegium Pharmaceutical, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Collegium Pharmaceutical, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Collegium Pharmaceutical, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.